GeoVax Labs Inc (GOVX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.36 (-6.81%), Market cap $0.00B, 52-week low–high $0.16 ~ $3.57.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatm
Financial statements, price targets, institutional (13F) holdings and related news for GeoVax Labs Inc are updated in real time on BlackAll Trade.
GeoVax Labs Inc trades at $0.36 (-6.81%). Real-time quotes and charts are available on BlackAll Trade.
GeoVax Labs Inc has a market cap of about $0.00B.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the Unit